Exploration of screening criteria for healthy volunteers in human bioequivalence clinical trials / 中国临床药理学与治疗学

Human bioequivalence testing is an important part of evaluating the quality of a formulation. Although these drugs have a large amount of safety data and clinical application data, they may still have ethical risks in healthy subjects. The definition of healthy volunteers, the general inclusion and exclusion criteria, auxiliary inclusion and exclusion criteria, and inclusion and exclusion criteria considering drug specificity are summarized. The basis for determining whether abnormal test values are clinically significant when screening healthy subjects and the considerations for improving the screening pass rate are discussed. It is expected to provide useful reference for the smooth implementation of human bioequivalence testing.

Criteria and Ethical Issues for Clinical Research of Spinal Cord Injury (review) / 中国康复理论与实践

The outcome of spinal cord injury is related to many factors, such as mechanism and severity of injury, and differences of individual. The standard of clinical trial plays a very important role in the reliability of the research. especially the inclusion and exclusion criterias, ethical issues, treatment standardization, informed consent and other issues. The effect of these factors on the clinical trial of spinal cord injury was summarized in this article. The inclusion and exclusion criterias to control the consistency should be developed based on the specific research content. Informed consent for clinical trial is also necessary, especially to the clinical trials with uncertainly benefits and risks, as well as the standardization of the operation procedures and rehabilitation treatment.

Repeated microendoscopic discectomy for recurrent lumbar disk herniation

OBJECTIVES: To explore the microendoscopic discectomy technique and inclusion criteria for the treatment of recurrent lumbar disc herniation and to supply feasible criteria and technical notes to avoid complications and to increase the therapeutic effect. METHODS: A consecutive series of 25 patients who underwent posterior microendoscopic discectomy for recurrent lumbar disc herniation were included. The inclusion criteria were as follows: no severe pain in the lumbar region, no lumbar instability observed by flexion-extension radiography and no intervertebral discitis or endplate damage observed by magnetic resonance imaging. All patients were diagnosed by clinical manifestations and imaging examinations. RESULTS: Follow-up visits were carried out in all cases. Complications, such as nerve injuries, were not observed. The follow-up outcomes were graded using the MacNab criteria. A grade of excellent was given to 12 patients, good to 12 patients and fair to 1 patient. A grade of excellent or good occurred in 96% of cases. One patient relapsed 3 months after surgery and then underwent lumbar interbody fusion and inner fixation. The numerical rating scale of preoperative leg pain was 7.4± 1.5, whereas it decreased to 2.1±0.8 at 7 days after surgery. The preoperative Oswestry disability index of lumbar function was 57.5±10.0, whereas it was 26.0±8.5 at 7 days after surgery. CONCLUSION: In these cases, microendoscopic discectomy was able to achieve satisfactory clinical results. Furthermore, it has advantages over other methods because of its smaller incision, reduced bleeding and more efficient recovery. .

Propuesta de normativa de registro sanitario para los "medicamentos huérfanos" en la República Bolivariana de Venezuela / Proposal for a health registration regulation for "orphan drugs" in the Bolivarian Republic of Venezuela

Los medicamentos huérfanos son aquellos requeridos para diagnosticar, prevenir o tratar enfermedades poco frecuentes, pero que pueden ser graves y debilitantes. Este trabajo tiene como objetivo proponer la implementación de una normativa de registro sanitario específica para los medicamentos huérfanos en la República Bolivariana de Venezuela, considerando la situación actual de salud y las necesidades de la población, a fin llegar a todos los niveles, facilitando la disponibilidad del mayor número de medicamentos que son requeridos por un grupo reducido de pacientes. Es necesario que las autoridades sanitarias en Venezuela fortalezcan el sistema de salud pública estableciendo políticas para satisfacer las necesidades de la población en general pero que también incluya a las minorías. Se plantean las consideraciones técnicas, legales, fiscales y regulatorias necesarias para la implementación de esta normativa, así como los criterios de inclusión para clasificar un medicamento dentro la categoría de "huérfanos". La metodología utilizada fue de tipo documental, haciendo énfasis en el análisis teórico y conceptual del material a fin de elaborar la propuesta de la normativa para medicamentos huérfanos en la República Bolivariana de Venezuela. Se realizó un análisis teórico de la información obtenida para determinar la situación actual nacional e internacional a fin de obtener los resultados que sirvieron de base para desarrollar la propuesta.

Orphan drugs are those required to diagnose, prevent or treat rare diseases but that may be severe and debilitating; besides, reduce the quality of life of patients and their families. This project aims to propose a special regulation for Orphan Drugs in the Bolivarian Republic of Venezuela taking into account the current health situation and needs of the population in order to reach all levels by facilitating the availability of a bigger amount of drugs required by a small group of patients. It is necessary for health authorities in Venezuela to strengthen the public health system by establishing policies to meet the needs of general population but also include minorities. Technical, legal and regulatory considerations arise for the implementation of this normative, as well as the inclusion criteria for drugs within the category of "orphans". The methodology used is documentary, as it emphasizes the theoretical and conceptual analysis of the material for the proposed regulation for orphan drugs in the Bolivarian Republic of Venezuela. A theoretical analysis of the information was made to determine the current national and international situation in order to obtain the results as a basis to develop the proposal.

Some of problems in inclusion criteria and evaluation indexes of clinical trials in traditional herbs medicine for patients with cerebral infarction / 中国临床药理学与治疗学

Depending upon the characteristics of the pathological and clinical types encountered, inclusion criteria and evaluation indexes should be done in accordance with the treatment purpose. The duration of the trail, types and degree of the infarction should be delaminated, and the relationship between these factors and the evaluative indexes analized. A standardized procedures for clinical trials on cerebral infarction should be established for clinical trails of Traditional Chinese Medicine.